A case report of long-term successful use of maintenance therapy with PARP inhibitors in the primary treatment of advanced BRCA-associated ovarian cancer
Background. Ovarian cancer is the third most common cancer of the female reproductive system after cervical and uterine cancer and is diagnosed at stage III–IV in 2 out of 3 cases. Maintenance therapy with PARP inhibitors signifcantly prolongs disease-free and overall survival. The purpose of the st...
Saved in:
| Main Authors: | О. N. Churuksaeva, L. А. Kolomiets, А. B. Villert |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2023-09-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/2689 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A clinical case of repeat use of PARP inhibitors in a patient with <i>mBRCA</i>-associated ovarian cancer
by: A. B. Villert, et al.
Published: (2022-09-01) -
The evolving role of PARP inhibitors in advanced ovarian cancer
by: Levva Sofia, et al.
Published: (2021-08-01) -
Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review
by: K. V. Menshikov, et al.
Published: (2022-06-01) -
Comparative characteristics of the effectiveness of therapy with PARP inhibitor in patients with primary ovarian cancer in the Tyumen Region in the period from 2019 to 2023
by: M. Ya. Kuzmenko, et al.
Published: (2025-05-01) -
First‐In‐Human Dose Finding Study of Venadaparib (IDX‐1197), a Potent and Selective PARP Inhibitor, in Patients With Advanced Solid Tumors
by: Sung‐Bae Kim, et al.
Published: (2025-02-01)